Document is current
Any future updates will be listed below
-
Authors
Sleiman, Yvonne
Reiken, Steven
Charrabi, Azzouz
Jaffré, Fabrice
Sittenfeld, Leah R.
Pasquié, Jean-Luc
Colombani, Sarah
Lerman, Bruce B.
Chen, Shuibing
Marks, Andrew R.
Cheung, Jim W.
Evans, Todd
Lacampagne, Alain
Meli, Albano C. http://orcid.org/0000-0002-1727-3027
-
Funding
Funding for this research was provided by:
Fondation coeur et recherche (SUDEPSY)
- License Information
-
More Information
Article History
Received: 22 June 2023
Accepted: 14 September 2023
First Online: 23 September 2023
Declarations
:
: The patient carrying the RyR2-H29D mutation gave a written informed consent and agreed to participate and have blood samples obtained for hiPSC generation. This study was conducted in accordance with the Declaration of Helsinki and approved by the Cornell Institutional Review Board Committee of Weill Cornell Medicine. Title of the approved project: “Modeling Cardiac Ryanodine Receptor (RyR2) Mutations Causing Polymorphic Ventricular Tachycardia at Rest with Patient-Specific Induced Pluripotent Stem Cells”. Name of the institutional approval committee: Cornell Institutional Review Board Committee of Weill Cornell Medicine. Approval number: IRB Protocol 1502015884. Date of approval: December 2015.
: ARM is a board member and owns shares in ARMGO Pharma Inc., which is targeting RyR channels for therapeutic purposes. The other authors declare no conflict of interest.
